Status:
COMPLETED
MMF After Pediatric Liver Transplantation
Lead Sponsor:
Hannover Medical School
Conditions:
Liver Transplantation
Chronic Kidney Disease
Eligibility:
All Genders
Up to 17 years
Phase:
NA
Brief Summary
The use of CNIs (CSA or FK) as primary immunosuppressive drugs after pediatric liver transplantation is one of the main causes of chronic kidney disease in these patients in the long term. The study ...
Eligibility Criteria
Inclusion
- patients after pediatric liver transplantation
- no acute rejections for the last half year
Exclusion
- concomitant malign disease (e.g. ptld)
- neutropenia (granulocytes \<1000/µl)
- systemic infection
- thrombopenia (\<80/nl)
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00367146
Start Date
November 1 2004
End Date
August 1 2008
Last Update
May 20 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hannover medical School
Hanover, Germany, 30625